[Clinical trial of etophamide in the treatment of chronic intestinal amebiasis].
The author present the results obtained in the treatment of 100 patients suffering chronic intestinal amebiasis, employing a new drug--Etophamide, in a dose of 1,0 g per day, for three consecutive days. The tolerance of a new antiamebic drug was excellent in all patients, and the parasitological cure rate obtained was 92%. The author concluded that the new derivate amebicide used in this research is very effective for treatment of intestinal amebiasis infections.
D000081:Acetamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000563:Amebicides / Q000627:therapeutic use*; D002648:Child; D002908:Chronic Disease; D004341:Drug Evaluation; D004404:Dysentery, Amebic / Q000188:drug therapy*; D004987:Ethers / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000081:Acetamides; D000563:Amebicides; D004987:Ethers; C010151:etofamide
Ensaio clínico com etofamida no tratamento da  amebíase intestinal crônica.